Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... of the Phase 2b program to evaluate the Company's once-daily inhaled liposomal ciprofloxacin administered via nebulizer in patients with non-cystic fibrosis bronchiectasis are ...
2009 NOV 16 ... antibiotic therapy of bacteria[ infection. ALL were treated with a fluoroquinolone (ciprofloxacin or Levofloxacin) combined with rifampin (two cases) or flucloxacillin (three cases), ...
2009 NOV 16 ... ofloxacin at minimum inhibitory concentration (MIC) of 250 mc M. At this concentration, ciprofloxacin showed incomplete inhibition whereas metronidazole was inactive," wrote S. Sithiprom ...
2009 NOV 16 ... formation and cell viability when the organism was exposed to sub-MICs of ampicillin, ciprofloxacin, or tetracycline. The S. intermedius wild type (WT) and its isogenic luxS mutant, strain ...
2009 NOV 16 ... studied in detail, all of which had reduced susceptibility (MIC >= 0.125 mu g/ml) to ciprofloxacin but were either susceptible or showed only low-level resistance (MIC <= 32 mu g/ml) ...
2009 NOV 16 ... Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and ciprofloxacin-resistant Pseudomonas aeruginosa (CR-PA). Nares and rectal swabs were obtained before ...
2009 NOV 16 ... the impact of low-level resistance to fluoroquinolones on the bactericidal activity of ciprofloxacin in a murine model of urinary tract infection. The susceptible Escherichia coli strain ...
2009 NOV 16 ... EGDSA and PLRGK motifs. Second, dione-resistant gyrase and topo IV were inhibited by ciprofloxacin, whereas quinolone-resistant enzymes (GyrA S81F and ParC S79F) remained susceptible to ...
2009 NOV 16 ... the construction of an impedimetric immunosensor for the label-free detection of ciprofloxacin, an antibiotic belonging to synthetic fluoroquinolones. A ...
2009 NOV 16 ... to that antibiotic in that specialty. The total use of antibiotics and the use of ciprofloxacin (CIP), co-amoxicillin + clavulanic acid (AMCL) and first and second-generation ...
2009 NOV 16 ... we examined susceptibilities to beta-lactams, including piperacillin-tazobactam, and ciprofloxacin by microdilution and disk diffusion ( only for piperacillin-tazobactam) methods, against ...
2009 NOV 24 ... tobramycin, and clarithromycin), and 8 received dual therapy (clarithromycin and ciprofloxacin). The mean duration of treatment was 14 weeks ( range, 1-24 weeks). All of the patients ...
2009 NOV 17 ... for Tc-99m-sparafloxacin was 5.9+/-0.7, while that for the commercially available Tc-99m-ciprofloxacin was 3.8+/-0.5 under the same experimental paradigm, indicating that 99mTc-sparafloxacin ...
2009 NOV 16 ... effects of iron depletion on the antimicrobial activity of ceftazidime, tobramycin and ciprofloxacin against planktonic and biofilm Pseudomonas aeruginosa." "We tested the ...
2009 NOV 23 ... swine and swine workers. Two predominant multidrug resistance profiles were identified: ciprofloxacin/clindamycin/erythromycin/cefoxitin/gentamicin/tetracycline/chloramphenicol and...
2009 NOV 23 ... for ampicillin-sulbactam (SAM), 11.5% for trimethoprim-sulfamethoxazole (SXT), 5% for ciprofloxacin (CIP), 2.5% for nitrofurantoin (F/M), 0.5% for ceftazidime (CAZ), 0.5% for cefotaxime ...
2009 NOV 24 ... developed for the simultaneous determination of enrofloxacin and its active metabolite ciprofloxacin from urine samples. The molecularly imprinted monolithic columns were synthesized in ...
